Genetically modified virus therapy targeting HTLV-1, a carcinogenic virus

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K06911
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical genome science
• Research Institution: Kagoshima University
• Principal Investigator: Suzuki Shinsuke 鹿児島大学, 医歯学総合研究科, 特任講師 (20437974)
• Co-Investigator(Renkei-kenkyūsha): KOSAI Kenichirou 鹿児島大学, 大学院医歯学総合研究科先進治療科学専攻 運動機能修復学講座遺伝子治療・再生医学分野, 教授 (90258418) ; UENO Shinichi 鹿児島大学, 大学院医歯学総合研究科先進治療科学専攻臨床腫瘍学講座, 特任講師 (40322317) ; 魚住 公治 独立行政法人国立病院機構, 鹿児島医療 センター(臨床研究部), 腫瘍内科部長 (90253864)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 成人T細胞性白血病 / 特異的増殖型アデノウイルス / HTLV-1 bZIP factor

Outline of Final Research Achievements

We aimed to establish a novel treatment by conditionally replicating adenovirus (CRA) targeted to human T cell leukemia virus type I (HTLV-1). HTLV-1 is a causative virus of adult T-cell leukemia (ATL). We reconfirmed that the HTLV-1 bZIP factor (HBZ) gene is expressed in HTLV-1 infected cells. We are developing HBZ promoter-dependent CRA (HBZ.CRA) that erades only HTLV-1 infected cells.

Free Research Field

造血器腫瘍